TABLE 1.
Baseline characteristics of IBD patients, by study group
| Characteristics | Elderly | Nonelderly | p value |
|---|---|---|---|
| Age, years, median (range) | 70.3 (65.2–90.0) | 46.8 (19.0–64.9) | <0.001 |
| Female sex, n (%) | 67 (33.8) | 117 (29.5) | ns |
| Weight, kg, mean (SD) | 67.6 (13.1) | 69.7 (13.6) | ns |
| Current smoker, n (%) | 63 (31.8) | 134 (33.8) | ns |
| Disease duration, years, median (range) | 8.3 (0.2–48.3) | 10.5 (0–59.7) | ns |
| Perianal disease, n (%) | 14 (7.1) | 54 (13.6) | 0.018 |
| Extra‐intestinal manifestations, n (%) | 22 (11.1) | 91 (22.9) | ns |
| History of cancer, n (%) | 31 (15.7) | 39 (9.8) | 0.038 |
| Previous immunosuppressive therapy, n (%) | 93 (46.9) | 257 (64.9) | <0.001 |
| Previous exposure to anti‐TNF‐α agents, n (%) | 87 (43.9) | 255 (64.4) | <0.001 |
| Concomitant therapies, n (%) | |||
| 5ASA | 87 (43.9) | 152 (38.4) | ns |
| 5ASA + IMM | 3 (1.5) | 18 (4.5) | ns |
| IMM | 5 (2.5) | 20 (5.1) | ns |
| Steroids | 102 (51.5) | 172 (43.4) | ns |
| CRP (mg/dl), mean (SD) | 13.4 (17.9) | 10.9 (21.0) | ns |
| CCI, mean (SD) | 3.31 (1.37) | 3.29 (1.39) | ns |
| Comorbidities, n (%) | 100 (50.5) | 131 (33.1) | <0.001 |
| CD | 90 (45.5) | 191 (48.2) | ns |
| Age, years, median (range) | 70.4 (65.3–85.9) | 45.1 (19.3–64.7) | <0.001 |
| Female sex, n (%) | 39 (43.3) | 50 (26.2) | 0.004 |
| Weight, kg, mean (SD) | 63.0 (12.8) | 67.6 (13.8) | ns |
| Current smoker, n (%) | 32 (35.6) | 81 (42.2) | ns |
| Disease duration, years, median (range) | 9.2 (0.3–48.3) | 11.3 (0.0–59.7) | ns |
| Localization | |||
| L1 | 39 (43.3) | 91 (47.6) | ns |
| L2 | 9 (10.0) | 26 (13.6) | ns |
| L3 | 40 (44.4) | 71 (37.2) | ns |
| L4 | 2 (2.2) | 3 (1.6) | ns |
| Behaviour | |||
| B1 | 26 (28.9) | 56 (29.3) | ns |
| B2 | 51 (56.7) | 94 (49.2) | ns |
| B3 | 13 (14.4) | 41 (21.5) | ns |
| Disease activity (HBI), n (%) | |||
| <5 | 12 (13.3) | 21 (11.0) | ns |
| 5–7 | 24 (26.7) | 47 (24.6) | ns |
| 8–16 | 52 (57.8) | 115 (60.2) | ns |
| >16 | 2 (2.2) | 8 (4.2) | ns |
| Endoscopic activity (SES‐CD), n (%) | |||
| 0–2 | 3 (3.3) | 8 (4.2) | ns |
| 3–6 | 13 (14.4) | 31 (16.2) | ns |
| 7–15 | 57 (63.3) | 108 (56.5) | ns |
| >15 | 17 (18.9) | 44 (23.0) | ns |
| Perianal disease, n (%) | 13 (14.4) | 46 (24.1) | ns |
| Extra‐intestinal manifestations, n (%) | 14 (15.6) | 52 (27.2) | ns |
| History of cancer, n (%) | 15 (16.7) | 27 (14.1) | ns |
| Previous immunosuppressive therapy, n (%) | 44 (48.9) | 134 (70.2) | 0.001 |
| Previous exposure to anti‐TNF‐α agents, n (%) | 43 (47.8) | 137 (71.7) | <0.001 |
| Concomitant therapies, n (%) | |||
| 5ASA | 21 (23.3) | 37 (19.4) | ns |
| 5ASA + IMM | 0 (0.0) | 3 (1.6) | ns |
| IMM | 2 (2.2) | 12 (6.3) | ns |
| Steroids | 69 (36.1) | 43 (47.8) | ns |
| Previous CD surgery, n (%) | 50 (25.3) | 118 (29.8) | ns |
| CRP (mg/dl), mean (SD) | 12.8 (16.9) | 12.1 (16.6) | ns |
| CCI, mean (SD) | 4.0 (0.99) | 2.4 (1.35) | ns |
| Comorbidities, n (%) | 45 (50.0) | 67 (35.1) | 0.017 |
| UC | 108 (54.5) | 205 (51.8) | ns |
| Age, years, median (range) | 70.2 (65.2–90.0) | 48.0 (19.0–64.9) | <0.001 |
| Female sex, n (%) | 28 (25.9) | 67 (32.7) | ns |
| Weight, kg, mean (SD) | 71.0 (12.4) | 71.9 (13.2) | ns |
| Current smoker, n (%) | 31 (28.7) | 53 (25.9) | ns |
| Disease duration, years, median (range) | 7.6 (0.2–40.5) | 9.4 (0.1–40.7) | ns |
| Extension | |||
| E1 | 3 (2.8) | 12 (5.9) | ns |
| E2 | 50 (46.3) | 103 (50.2) | ns |
| E3 | 55 (50.9) | 90 (43.9) | ns |
| Disease activity (PMS), n (%) | |||
| 0–2 | 5 (4.6) | 5 (2.4) | ns |
| 2–4 | 19 (17.6) | 44 (21.5) | ns |
| 5–7 | 58 (53.7) | 119 (58.0) | ns |
| >7 | 26 (24.1) | 37 (18.0) | ns |
| Endoscopic activity (endoscopic MS), n (%) | |||
| 0 | 2 (1.9) | 2 (1.0) | ns |
| 1 | 5 (4.6) | 15 (7.3) | ns |
| 2 | 46 (42.6) | 105 (51.2) | ns |
| 3 | 55 (50.9) | 83 (40.5) | ns |
| Perianal disease, n (%) | 1 (0.9) | 8 (3.9) | ns |
| Extra‐intestinal manifestations, n (%) | 8 (7.4) | 39 (19.0) | ns |
| History of cancer, n (%) | 16 (14.8) | 12 (5.9) | 0.008 |
| Previous immunosuppressive therapy, n (%) | 49 (45.4) | 123 (60.0) | 0.013 |
| Previous exposure to anti‐TNF‐α agents, n (%) | 44 (40.7) | 118 (57.6) | 0.005 |
| Concomitant therapies, n (%) | |||
| 5ASA | 66 (61.1) | 115 (56.1) | ns |
| 5ASA + IMM | 3 (2.8) | 15 (7.3) | ns |
| IMM | 3 (2.8) | 8 (3.9) | ns |
| Steroids | 59 (54.6) | 103 (50.2) | ns |
| CRP (mg/dl), mean (SD) | 13.5 (18.0) | 11.0 (21.1) | ns |
| CCI, mean (SD) | 3.88 (1.13) | 3.34 (1.35) | ns |
| Comorbidities, n (%) | 55 (50.9) | 64 (31.2) | 0.001 |
Abbreviations: ASA, acetylsalicylic acid; CCI, Charlson comorbidity index; CD, Crohn’s disease; CRP, C‐reactive protein; HBI, Harvey–Bradshaw Index; IMM, Immunosuppressants; MS, Mayo score; ns, not significant; PMS, partial Mayo score; SES‐CD; Simple Endoscopic Score for Crohn’s Disease; TNF, tumour necrosis factor; UC, ulcerative colitis. Bold values indicates p value 0.53.